BCRX
Price
$8.60
Change
+$0.24 (+2.87%)
Updated
Aug 6 closing price
Capitalization
1.81B
83 days until earnings call
SGMO
Price
$0.53
Change
-$0.00 (-0.00%)
Updated
Aug 6 closing price
Capitalization
130.04M
Earnings call today
Interact to see
Advertisement

BCRX vs SGMO

Header iconBCRX vs SGMO Comparison
Open Charts BCRX vs SGMOBanner chart's image
BioCryst Pharmaceuticals
Price$8.60
Change+$0.24 (+2.87%)
Volume$2.68M
Capitalization1.81B
Sangamo Therapeutics
Price$0.53
Change-$0.00 (-0.00%)
Volume$4.3M
Capitalization130.04M
BCRX vs SGMO Comparison Chart in %
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SGMO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCRX vs. SGMO commentary
Aug 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Buy and SGMO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 07, 2025
Stock price -- (BCRX: $8.60 vs. SGMO: $0.53)
Brand notoriety: BCRX: Notable vs. SGMO: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 73% vs. SGMO: 72%
Market capitalization -- BCRX: $1.81B vs. SGMO: $130.04M
BCRX [@Biotechnology] is valued at $1.81B. SGMO’s [@Biotechnology] market capitalization is $130.04M. The market cap for tickers in the [@Biotechnology] industry ranges from $210.97B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 0 FA rating(s) are green whileSGMO’s FA Score has 0 green FA rating(s).

  • BCRX’s FA Score: 0 green, 5 red.
  • SGMO’s FA Score: 0 green, 5 red.
According to our system of comparison, BCRX is a better buy in the long-term than SGMO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 5 TA indicator(s) are bullish while SGMO’s TA Score has 5 bullish TA indicator(s).

  • BCRX’s TA Score: 5 bullish, 3 bearish.
  • SGMO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, BCRX is a better buy in the short-term than SGMO.

Price Growth

BCRX (@Biotechnology) experienced а +4.62% price change this week, while SGMO (@Biotechnology) price change was -2.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.54%. For the same industry, the average monthly price growth was +12.42%, and the average quarterly price growth was +13.42%.

Reported Earning Dates

BCRX is expected to report earnings on Oct 29, 2025.

SGMO is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (-0.54% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCRX($1.81B) has a higher market cap than SGMO($130M). BCRX YTD gains are higher at: 14.362 vs. SGMO (-48.049). BCRX has higher annual earnings (EBITDA): 47.6M vs. SGMO (-72.14M). BCRX has more cash in the bank: 295M vs. SGMO (25.2M). SGMO has less debt than BCRX: SGMO (24.9M) vs BCRX (795M). BCRX has higher revenues than SGMO: BCRX (503M) vs SGMO (63.8M).
BCRXSGMOBCRX / SGMO
Capitalization1.81B130M1,388%
EBITDA47.6M-72.14M-66%
Gain YTD14.362-48.049-30%
P/E RatioN/AN/A-
Revenue503M63.8M788%
Total Cash295M25.2M1,171%
Total Debt795M24.9M3,193%
FUNDAMENTALS RATINGS
BCRX vs SGMO: Fundamental Ratings
BCRX
SGMO
OUTLOOK RATING
1..100
5869
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
79
Overvalued
PROFIT vs RISK RATING
1..100
82100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6265
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for SGMO (79). This means that BCRX’s stock grew somewhat faster than SGMO’s over the last 12 months.

BCRX's Profit vs Risk Rating (82) in the Biotechnology industry is in the same range as SGMO (100). This means that BCRX’s stock grew similarly to SGMO’s over the last 12 months.

BCRX's SMR Rating (100) in the Biotechnology industry is in the same range as SGMO (100). This means that BCRX’s stock grew similarly to SGMO’s over the last 12 months.

BCRX's Price Growth Rating (62) in the Biotechnology industry is in the same range as SGMO (65). This means that BCRX’s stock grew similarly to SGMO’s over the last 12 months.

BCRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as SGMO (100). This means that BCRX’s stock grew similarly to SGMO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXSGMO
RSI
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 8 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 29 days ago
79%
Bullish Trend 14 days ago
74%
Declines
ODDS (%)
Bearish Trend 6 days ago
80%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SGMO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CLGRX71.68N/A
N/A
Calvert US Large Cap Growth Rspnb Idx R6
FMXSX8.03N/A
N/A
Federated Hermes Max-Cap Index Svc
STPAX22.70N/A
N/A
Saratoga Technology & Comm A
TTMIX168.75N/A
N/A
T. Rowe Price Comm & Tech I
HASCX40.78-0.17
-0.42%
Harbor Small Cap Value Instl